FRAMINGHAM, Mass. and SYDNEY, July 27 HeartWare International, Inc. (Nasdaq: HTWR, ASX:HIN) will release financial results for the second quarter and six months ended June 30, 2010 after the close of the U.S. markets on Thursday, August 5, 2010.
A conference call with management is scheduled for 5:00 pm U.S. Eastern Time on Thursday, August 5, 2010 (7:00 am Australian Eastern Standard Time on Friday, August 6, 2010) to discuss the Company's financial results, quarterly highlights and business outlook. The call may be accessed by dialing 1-877-407-0789 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the United States, dial + 1-201-689-8562.
A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Second Quarter Conference Call" under the section titled "Corporate Presentations" on the Home Page. A replay of the conference call will be available through the above weblink immediately following completion of the call.
A copy of the press release announcing results and related information will be available on the Company's web site, www.heartware.com.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol. For additional information, please visit the company's website at www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
For further information: ------------------------ Christopher Taylor HeartWare International, Inc. Email: [email protected]
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.